UK’s NHS Hires US ‘Spy-Tech’ Firm Palantir To Extract Patient Data Without Patient Consent
Palantir, with intimate ties to defense, intelligence and security industries around the world, is set to play an even larger role in the UK’s crisis-ridden National Health System (NHS).
Last summer, as readers may recall, executives at NHS England — the non-departmental government body that runs the National Health Service in England — came up with an ingenious plan to digitally scrape the general practice data of up to 55 million patients and share it with any private third parties willing to pay for it. NHS England allowed patients to opt out of the scheme; they just didn’t bother telling them about it until three weeks before the deadline, presumably because if they had, millions of patients would have opted out.
When the FT finally broke the story, a scandal erupted. NHS England officials responded by shelving the scheme, saying they needed to focus on reaching out to patients and reassuring them their data is safe. But that hasn’t happened. Instead, they have waited for the scandal to die down before embarking on an even more egregious scheme.
This time it is patient data from UK hospitals that is up for grabs. And patients will have no opt-out option. In fact, without even consulting patients, NHS England has instructed NHS Digital — which will soon be merged with NHS England as part of the UK’s governments accelerated reforms to the NHS’ “tech agenda” — to gather patient data from NHS hospitals and extract it to its data platform, which is based on Palantir’s Foundry enterprise data management platform.
The pretext for taking such a step is that researching and analyzing patients’ hospital data will help the NHS better understand and tackle the crisis in treatment waiting times resulting from the COVID-19 pandemic. But the result will be yet more private-sector involvement in essential NHS processes. And in this case, the company being involved in those processes is one of the darkest in the tech universe. – READ MORE
Responses